| [1] |
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020[J]. CA Cancer J Clin, 2020, 70(1):7-30.
|
| [2] |
Aier I, Semwal R, Sharma A, et al. A systematic assessment of statistics, risk factors, and underlying features involved in pancreatic cancer[J]. Cancer Epidemiol, 2019(58):104-110.
|
| [3] |
Rahib L, Smith BD, Aizenberg R, et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States[J]. Cancer Res, 2014, 74(11): 2913-2921.
|
| [4] |
Canto MI, Almario JA, Schulick RD, et al. Risk of neoplastic progression in individuals at high risk for pancreatic cancer undergoing long-term surveillance[J]. Gastroenterology, 2018, 155(3):740-751, e2.
|
| [5] |
Kamisawa T, Wood LD, Itoi T, et al. Pancreatic cancer[J]. Lancet, 2016, 388(10039):73-85.
|
| [6] |
Demir IE, Jäger C, Schlitter AM, et al. R0 versus R1 resection matters after pancreaticoduodenectomy, and less after distal or total pancreatectomy for pancreatic cancer[J]. Ann Surg, 2018, 268(6): 1058-1068.
|
| [7] |
Mokdad AA, Minter RM, Zhu H, et al. Neoadjuvant therapy followed by resection versus upfront resection for resectable pancreatic cancer: a propensity score matched analysis[J]. J Clin Oncol, 2017, 35(5): 515-522.
|
| [8] |
La Torre M, Nigri G, Lo Conte A, et al. Is a preoperative assessment of the early recurrence of pancreatic cancer possible after complete surgical resection?[J]. Gut Liver, 2014, 8(1):102-108.
|
| [9] |
Nishio K, Kimura K, Amano R, et al. Preoperative predictors for early recurrence of resectable pancreatic cancer[J]. World J Surg Oncol, 2017, 15(1):16.
|
| [10] |
Masui T, Doi R, Kawaguchi Y, et al. Concurrent gemcitabine+S-1 neoadjuvant chemotherapy contributes to the improved survival of patients with small borderline-resectable pancreatic cancer tumors[J]. Surg Today, 2016, 46(11):1282-1289.
|
| [11] |
Clavien PA, Barkun J, de Oliveira ML, et al. The Clavien-Dindo classification of surgical complications: five-year experience[J]. Ann Surg, 2009, 250(2):187-196.
|
| [12] |
Allen PJ, Kuk D, Castillo CF, et al. Multi-institutional validation study of the American Joint Commission on Cancer (8th Edition) changes for T and N staging in patients with pancreatic adenocarcinoma[J]. Ann Surg, 2017, 265(1):185-191.
|
| [13] |
Tempero MA, Malafa MP, Chiorean EG, et al. Pancreatic adenocarcinoma, version 1.2019[J]. J Natl Compr Canc Netw, 2019, 17(3):202-210.
|
| [14] |
Nagakawa Y, Sahara Y, Hosokawa Y, et al. Clinical impact of neoadjuvant chemotherapy and chemoradiotherapy in borderline resectable pancreatic cancer: analysis of 884 patients at facilities specializing in pancreatic surgery[J]. Ann Surg Oncol, 2019, 26(6): 1629-1636.
|
| [15] |
Motoi F, Kosuge T, Ueno H, et al. Randomized phase Ⅱ/Ⅲ trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP05)[J].Jpn J Clin Oncol, 2019, 49(2):190-194.
|
| [16] |
Okano K, Suto H, Oshima M, et al. A prospective phase Ⅱ trial of neoadjuvant S-1 with concurrent hypofractionated radiotherapy in patients with resectable and borderline resectable pancreatic ductal adenocarcinoma[J]. Ann Surg Oncol, 2017, 24(9):2777-2784.
|
| [17] |
Uesaka K, Boku N, Fukutomi A, et al. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01)[J]. Lancet, 2016, 388(10041):248-257.
|
| [18] |
Hayashi T, Nakamura T, Kimura Y, et al. Phase 2 study of neoadjuvant treatment of sequential S-1-based concurrent chemoradiation therapy followed by systemic chemotherapy with gemcitabine for borderline resectable pancreatic adenocarcinoma (HOPS-BR 01)[J]. Int J Radiat Oncol Biol Phys, 2019, 105(3):606-617.
|
| [19] |
Sinn M, Bahra M, Liersch T, et al. CONKO-005: adjuvant chemotherapy with gemcitabine plus erlotinib versus gemcitabine alone in patients after R0 resection of pancreatic cancer: a multicenter randomized phase Ⅲ trial[J]. J Clin Oncol, 2017, 35(29):3330-3337.
|
| [20] |
Maeda A, Boku N, Fukutomi A, et al. Randomized phase Ⅲ trial of adjuvant chemotherapy with gemcitabine versus S-1 in patients with resected pancreatic cancer: Japan Adjuvant Study Group of Pancreatic Cancer (JASPAC-01)[J]. Jpn J Clin Oncol, 2008, 38(3): 227-229.
|
| [21] |
Tran NH, Sahai V, Griffith KA, et al. Phase 2 trial of neoadjuvant FOLFIRINOX and intensity modulated radiation therapy concurrent with fixed-dose rate-gemcitabine in patients with borderline resectable pancreatic cancer[J]. Int J Radiat Oncol Biol Phys, 2020, 106(1):124-133.
|
| [22] |
Reni M, Balzano G, Zanon S, et al. Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): a randomised, open-label, phase2-3 trial[J]. Lancet Gastroenterol Hepatol, 2018, 3(6):413-423.
|
| [23] |
Miyasaka Y, Ohtsuka T, Kimura R, et al. Neoadjuvant chemotherapy with gemcitabine plus nab-paclitaxel for borderline resectable pancreatic cancer potentially improves survival and facilitates surgery[J]. Ann Surg Oncol, 2019, 26(5):1528-1534.
|
| [24] |
Macedo FI, Ryon E, Maithel SK, et al. Survival outcomes associated with clinical and pathological response following neoadjuvant FOLFIRINOX or gemcitabine/nab-paclitaxel chemotherapy in resected pancreatic cancer[J]. Ann Surg, 2019, 270(3):400-413.
|
| [25] |
Choi JG, Nipp RD, Tramontano A, et al. Neoadjuvant FOLFIRINOX for patients with borderline resectable or locally advanced pancreatic cancer: results of a decision analysis[J]. Oncologist, 2019, 24(7):945-954.
|